MRX · Marex Group Ltd

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.17 to $62.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.16 to $62.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.105 to $61.1, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.645 to $64.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.66 to $65.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.66 to $66.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.65 to $65.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.66 to $64.6533, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.715 to $65.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.965 to $62.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.945 to $63.075, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.945 to $61.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $61.81 to $62.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.81 to $63.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein includes 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein includes 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein includes 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein includes 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein includes 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The number of ordinary shares reported herein consists of 2,070 shares underlying restricted share awards granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.775 to $53.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying restricted share awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 29, 2026.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying restricted share awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 29, 2026.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $53.775 to $54.155, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 150,563 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying restricted share awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 29, 2026.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 111,183 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 150,563 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 272,659 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 25,300 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Represents the number of ordinary shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported shares underlying deferred bonus plan awards.

The price reported represents the closing price of the Issuer's ordinary shares on the Nasdaq Stock Market LLC on May 21, 2026.

The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $55.06 to $56.055 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $56.065 to $56.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.42 to $53.415, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $53.42 to $53.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 192,348 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $50.51 to $51.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $51.56 to $52.115 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 383,741 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $52.09 to $52.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 286,871 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $51.08 to $52.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $50.07 to $51.065 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $43.77 to $44.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 192,348 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $42.77 to $43.7650 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on September 10, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $42.77 to $43.7650 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on December 12, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $43.77 to $44.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number of ordinary shares reported herein includes 383,741 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.